Phytochemical Approach and Bioanalytical Strategy to Develop Chaperone-Based Medications
Identifiers and Pagination:Year: 2008
First Page: 44
Last Page: 48
Publisher ID: TOBIOCJ-2-44
Article History:Received Date: 22/2/2008
Revision Received Date: 19/3/2008
Acceptance Date: 25/3/2008
Electronic publication date: 29/4/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
Currently, no pharmaceuticals for the etiological treatment of degenerative protein-misfolding diseases (e.g., ALS, Alzheimer’s or prion diseases) are commercially available. In this technical note theoretical considerations and practical approaches concerning the development of chaperone-based medications from medicinal plants (e.g., Ginkgo biloba) are reviewed and discussed in detail. Phytochaperones and other agents isolated from medicinal plants are proposed to serve as the general basis of drug development in protein-misfolding diseases.